These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 38692865)

  • 1. New Directions for Advanced Targeting Strategies of EGFR Signaling in Cancer.
    Zhou Y; Takahashi JI; Sakurai H
    Biol Pharm Bull; 2024; 47(5):895-903. PubMed ID: 38692865
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic strategies utilized in the setting of acquired resistance to EGFR tyrosine kinase inhibitors.
    Yu HA; Riely GJ; Lovly CM
    Clin Cancer Res; 2014 Dec; 20(23):5898-907. PubMed ID: 25303979
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Drug resistance of targeted therapy for advanced non-small cell lung cancer harbored EGFR mutation: from mechanism analysis to clinical strategy.
    Zhao Y; Wang H; He C
    J Cancer Res Clin Oncol; 2021 Dec; 147(12):3653-3664. PubMed ID: 34661758
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Advances in molecular-based personalized non-small-cell lung cancer therapy: targeting epidermal growth factor receptor and mechanisms of resistance.
    Jotte RM; Spigel DR
    Cancer Med; 2015 Nov; 4(11):1621-32. PubMed ID: 26310719
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Emerging paradigms and recent progress in targeting ErbB in cancers.
    Stoup N; Liberelle M; Lebègue N; Van Seuningen I
    Trends Pharmacol Sci; 2024 Jun; 45(6):552-576. PubMed ID: 38797570
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Resistance to anti-EGFR therapies in metastatic colorectal cancer: underlying mechanisms and reversal strategies.
    Zhou J; Ji Q; Li Q
    J Exp Clin Cancer Res; 2021 Oct; 40(1):328. PubMed ID: 34663410
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic targeting of epidermal growth factor receptor in human cancer: successes and limitations.
    Wykosky J; Fenton T; Furnari F; Cavenee WK
    Chin J Cancer; 2011 Jan; 30(1):5-12. PubMed ID: 21192840
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular-Targeted Therapies for Epidermal Growth Factor Receptor and Its Resistance Mechanisms.
    Yamaoka T; Ohba M; Ohmori T
    Int J Mol Sci; 2017 Nov; 18(11):. PubMed ID: 29140271
    [TBL] [Abstract][Full Text] [Related]  

  • 9. EGFR-TKIs resistance via EGFR-independent signaling pathways.
    Liu Q; Yu S; Zhao W; Qin S; Chu Q; Wu K
    Mol Cancer; 2018 Feb; 17(1):53. PubMed ID: 29455669
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Research Progress of Targeted Therapy for EGFR Gene in Non-small Cell Lung Cancer].
    Zhang H; Zhang S
    Zhongguo Fei Ai Za Zhi; 2017 Jan; 20(1):61-65. PubMed ID: 28103975
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutic targeting of the epidermal growth factor receptor in human cancer.
    Dhomen NS; Mariadason J; Tebbutt N; Scott AM
    Crit Rev Oncog; 2012; 17(1):31-50. PubMed ID: 22471663
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Update on recent preclinical and clinical studies of T790M mutant-specific irreversible epidermal growth factor receptor tyrosine kinase inhibitors.
    Liao BC; Lin CC; Lee JH; Yang JC
    J Biomed Sci; 2016 Dec; 23(1):86. PubMed ID: 27912760
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Mechanisms of Resistance to the Third-generation Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors in Non-small Cell Lung Cancer].
    Ni L; Nie L
    Zhongguo Fei Ai Za Zhi; 2018 Feb; 21(2):110-115. PubMed ID: 29526178
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New strategies in overcoming acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in lung cancer.
    Oxnard GR; Arcila ME; Chmielecki J; Ladanyi M; Miller VA; Pao W
    Clin Cancer Res; 2011 Sep; 17(17):5530-7. PubMed ID: 21775534
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epidermal growth factor receptor as a therapeutic target in glioblastoma.
    Kalman B; Szep E; Garzuly F; Post DE
    Neuromolecular Med; 2013 Jun; 15(2):420-34. PubMed ID: 23575987
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HER kinase activation confers resistance to MET tyrosine kinase inhibition in MET oncogene-addicted gastric cancer cells.
    Bachleitner-Hofmann T; Sun MY; Chen CT; Tang L; Song L; Zeng Z; Shah M; Christensen JG; Rosen N; Solit DB; Weiser MR
    Mol Cancer Ther; 2008 Nov; 7(11):3499-508. PubMed ID: 18974395
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Broad RTK-targeted therapy overcomes molecular heterogeneity-driven resistance to cetuximab via vectored immunoprophylaxis in colorectal cancer.
    Hu S; Dai H; Li T; Tang Y; Fu W; Yuan Q; Wang F; Lv G; Lv Y; Fan X; Zhang S; Jin R; Shen Y; Lin F; Ye X; Ding M; Yang Y; Lei C
    Cancer Lett; 2016 Nov; 382(1):32-43. PubMed ID: 27569653
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Current mechanism of acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitors and updated therapy strategies in human nonsmall cell lung cancer.
    Zhang K; Yuan Q
    J Cancer Res Ther; 2016 Dec; 12(Supplement):C131-C137. PubMed ID: 28230005
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacological background of EGFR targeting.
    Castillo L; Etienne-Grimaldi MC; Fischel JL; Formento P; Magné N; Milano G
    Ann Oncol; 2004 Jul; 15(7):1007-12. PubMed ID: 15205192
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of additional inhibition of human epidermal growth factor receptor 2 with the bispecific tyrosine kinase inhibitor AEE788 on the resistance to specific EGFR inhibition in glioma cells.
    Berezowska S; Diermeier-Daucher S; Brockhoff G; Busch R; Duyster J; Grosu AL; Schlegel J
    Int J Mol Med; 2010 Nov; 26(5):713-21. PubMed ID: 20878094
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.